Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 1/20 | 0.55 |
| ▸ | RARB | P10826 | 1/20 | 0.55 |
| ▸ | RARG | P13631 | 1/20 | 0.55 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.52 |
| ▸ | ACLY | P53396 | 2/20 | 0.50 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | CTSA | P10619 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2037082 | 0.84 | KDM1A (0.55) | RARARARBRARGPTGDR2XDH | |
| SCHEMBL29788150 | 0.84 | XDH (0.65) | XDHSLC22A12PDE4APDE4CPDE4D | |
| SCHEMBL2034067 | 0.84 | XDH (0.65) | XDHSLC22A12PDE4APDE4CPDE4D | |
| SCHEMBL28788990 | 0.84 | ROCK2 (0.51) | STK10SLKHPSEPTGDR2XDH | |
| SCHEMBL7553675 | 0.81 | RARA (0.58) | RARARARBRARGACLYHPSE | |
| SCHEMBL7607470 | 0.81 | KIT (0.51) | STK10SLKACLYCTSAKIT | |
| SCHEMBL2744330 | 0.79 | LMNA (0.54) | RARARARBRARGPTGDR2SLC22A12 | |
| SCHEMBL3138892 | 0.78 | SLC22A12 (0.66) | STK10SLKACLYHPSEXDH | |
| SCHEMBL7449464 | 0.77 | MEN1 (0.57) | RARARARBRARGPDE4APDE4C | |
| SCHEMBL17779981 | 0.77 | P4HB (0.44) | HPSEPTGDR2CTSAKITPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | MANLEY PAUL W (CH) | 2002-03-07 | — | — | US | claimed |
| US-6258843-B1 | DRUGS AS ENZYME INHIBITORS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | claimed |
| EP-0885193-A1 | TRIARYL COMPOUNDS | Novartis AG (CH) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032853-A1 | TRIARYL COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| US-6410547-B1 | (4-OXY-3-(ARYL)PHENYL)PYRIDINE FOR TREATMENT, PROPHYLAXIS OF INFLAMMATION, ESP. INFLAMMATORY OR OBSTRUCTIVE DISEASES OF THE AIRWAYS, E.G. FOR ASTHMA THERAPY; INHIBITORS OF PDE 4 ISOENZYME; DOWN REGULATE OR INHIBIT TNF-ALPHA RELEASE | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | MANLEY PAUL W (CH) | 2002-03-07 | — | — | US | disclosed |
| US-6288092-B1 | BIPHENYL PYRIDINES, BENZAMIDES AND PENYLCARBOXY COMPOUNDS USED AS SELECTIVE INHIBITORS OF PHOSPHODIESTERASE 4 ISOENZYME ACTIVITY AND DOWN REGULATORS OR INHIBIT TUMOR NECROSIS FACTOR RELEASE; ANTIHISTAMINES AND ANTIINFLAMMATORY | NOVARTIS AG (CH) | 2001-09-11 | — | — | US | disclosed |
| US-6258843-B1 | DRUGS AS ENZYME INHIBITORS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| US-6090817-A | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | NOVARTIS AG (CH) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | RARA 1743/4885RARB 1083/4885RARG 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.